Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of ZYN002 transdermal cannabidiol gel in Fragile X syndrome
2023-508165-33-00Phase 3Completed
- Sponsor
- Harmony Biosciences
- Start
- May 2024
- Modality
- Small Molecules, Transdermal Patches → Device-based Delivery → Drug Delivery Systems
- Countries
- 5
01
Overview
Phase 3, open-label, single-arm trial of Zygel in Fragile X syndrome (FXS), sponsored by Harmony Biosciences. Primary endpoint: Long-term safety and tolerability. Started May 2024; status: completed.
02
Drugs
Zygel
03
Conditions
Fragile X syndrome (FXS)
Beyond the preview
Go deeper on 2023-508165-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508165-33-00.